UA68326C2 - An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs - Google Patents

An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs Download PDF

Info

Publication number: UA68326C2
Authority: UA; Ukraine
Prior art keywords: virus; strain; vaccine; prrs; attenuated
Prior art date: 1996-01-25

Application number

UA97105158A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Hipra Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-25

Filing date

1996-04-12

Publication date

2004-08-16

1996-04-12 Application filed by Hipra Lab Sa filed Critical Hipra Lab Sa

2004-08-16 Publication of UA68326C2 publication Critical patent/UA68326C2/uk

Links

241000700605 Viruses Species 0.000 claims abstract description 102
230000002238 attenuated effect Effects 0.000 claims abstract description 42
229960005486 vaccine Drugs 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 18
208000011580 syndromic disease Diseases 0.000 claims abstract description 6
230000001850 reproductive effect Effects 0.000 claims abstract description 4
230000000241 respiratory effect Effects 0.000 claims abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
230000003612 virological effect Effects 0.000 claims description 17
241000282887 Suidae Species 0.000 claims description 16
230000010076 replication Effects 0.000 claims description 11
239000000427 antigen Substances 0.000 claims description 6
102000036639 antigens Human genes 0.000 claims description 6
108091007433 antigens Proteins 0.000 claims description 6
239000000758 substrate Substances 0.000 claims description 5
208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 3
239000002671 adjuvant Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
241000894006 Bacteria Species 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims description 2
239000003995 emulsifying agent Substances 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
230000003308 immunostimulating effect Effects 0.000 claims description 2
239000003381 stabilizer Substances 0.000 claims description 2
230000002779 inactivation Effects 0.000 claims 2
238000004108 freeze drying Methods 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000008569 process Effects 0.000 abstract description 2
LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 38
208000015181 infectious disease Diseases 0.000 description 27
241001465754 Metazoa Species 0.000 description 17
201000010099 disease Diseases 0.000 description 16
241000282898 Sus scrofa Species 0.000 description 7
230000000120 cytopathologic effect Effects 0.000 description 7
239000002356 single layer Substances 0.000 description 7
230000035935 pregnancy Effects 0.000 description 6
241000282693 Cercopithecidae Species 0.000 description 5
230000006978 adaptation Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000013553 cell monolayer Substances 0.000 description 4
210000003022 colostrum Anatomy 0.000 description 4
235000021277 colostrum Nutrition 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000725 suspension Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000035899 viability Effects 0.000 description 4
238000009007 Diagnostic Kit Methods 0.000 description 3
208000006265 Renal cell carcinoma Diseases 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
208000019465 refractory cytopenia of childhood Diseases 0.000 description 3
238000011160 research Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
206010020843 Hyperthermia Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010058874 Viraemia Diseases 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
210000001132 alveolar macrophage Anatomy 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000036031 hyperthermia Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000004922 lacquer Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
208000012153 swine disease Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
239000005723 virus inoculator Substances 0.000 description 2
206010000234 Abortion spontaneous Diseases 0.000 description 1
101100191372 Arabidopsis thaliana PRK5 gene Proteins 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
241000867607 Chlorocebus sabaeus Species 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000001951 Fetal Death Diseases 0.000 description 1
206010055690 Foetal death Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
241000710788 Lelystad virus Species 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000000656 anti-yeast Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
231100000479 fetal death Toxicity 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000834 fixative Substances 0.000 description 1
-1 for example Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
231100000516 lung damage Toxicity 0.000 description 1
239000000463 material Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
208000033937 musculocontractural type Ehlers-Danlos syndrome Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000032696 parturition Effects 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
238000007747 plating Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
208000002254 stillbirth Diseases 0.000 description 1
231100000537 stillbirth Toxicity 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10061—Methods of inactivation or attenuation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/815—Viral vaccine for porcine species, e.g. swine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

UA97105158A 1996-01-25 1996-04-12 An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs UA68326C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES09600168A ES2102971B1 (es)	1996-01-25	1996-01-25	Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
PCT/ES1996/000234 WO1997027288A1 (es)	1996-01-25	1996-12-04	Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion

Publications (1)

Publication Number	Publication Date
UA68326C2 true UA68326C2 (en)	2004-08-16

Family

ID=8293550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97105158A UA68326C2 (en)	1996-01-25	1996-04-12	An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs

Country Status (13)

Country	Link
US (1)	US6001370A (cs)
EP (1)	EP0835929A1 (cs)
JP (1)	JP3068204B2 (cs)
KR (1)	KR19980703268A (cs)
CN (1)	CN1185806A (cs)
BR (1)	BR9604888A (cs)
CA (1)	CA2216436A1 (cs)
CZ (1)	CZ286766B6 (cs)
ES (1)	ES2102971B1 (cs)
HU (1)	HUP9801124A3 (cs)
PL (1)	PL185841B1 (cs)
UA (1)	UA68326C2 (cs)
WO (1)	WO1997027288A1 (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69201441T3 (de) *	1991-06-06	2008-12-04	Boehringer Ingelheim Vetmedica Gmbh	Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
US6380376B1 (en) *	1992-10-30	2002-04-30	Iowa State University Research Foundation	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6773908B1 (en) *	1992-10-30	2004-08-10	Iowa State University Research Foundation, Inc.	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en) *	1992-10-30	2003-07-15	Iowa State University Research Foundation, Inc.	Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US5695766A (en) *	1992-10-30	1997-12-09	Iowa State University Research Foundation	Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
EP0839912A1 (en) *	1996-10-30	1998-05-06	Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo)	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040224327A1 (en) *	1996-10-30	2004-11-11	Meulenberg Johanna Jacoba Maria	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
WO2000047772A2 (en)	1999-02-10	2000-08-17	Genset	Polymorphic markers of the lsr gene
CA2366072C (en) *	1999-03-08	2007-07-10	Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V.	Prrsv vaccines
MXPA01010681A (es) *	1999-04-22	2003-08-20	Us Agriculture	Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado.
SG83740A1 (en) *	1999-08-10	2001-10-16	Inst Of Molecular Agrobiology	An attenuated porcine reproductive and respiratory syndrome virus strain and methods of use
US7338787B2 (en)	2000-01-14	2008-03-04	Serono Genetics Institute S.A.	Nucleic acids encoding OBG3 globular head and uses thereof
EP1156111A1 (en) *	2000-05-19	2001-11-21	Stichting Dienst Landbouwkundig Onderzoek	Chimeric arterivirus-like particles
WO2002046387A2 (en)	2000-12-07	2002-06-13	Syngenta Limited	Plant derived hydroxy phenyl pyruvate dioxygenases (hppd) resistant against triketone herbicides and transgenic plants containing these dioxygenases
PL214224B1 (pl) *	2001-01-30	2013-07-31	Lauridsen Group	Doustna forma koncentratu nie - hiperimmunizowanych nie-specyficznych immunoglobulin oraz suplement diety
KR20050040172A (ko) *	2003-10-27	2005-05-03	주식회사 중앙백신연구소	돼지 생식기호흡기 증후군 바이러스 불활화 백신의 제조방법
RU2007101725A (ru)	2004-06-18	2008-07-27	Риджентс Оф Дзе Юниверсити Оф Миннесота (Us)	Идентификация инфицированных вирусом и вакцинированных вирусом организмов
US7632636B2 (en)	2004-09-21	2009-12-15	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome isolates and methods of use
ATE479440T1 (de) *	2004-11-19	2010-09-15	Intervet Int Bv	Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen
CA2894069C (en)	2005-06-24	2019-02-26	Regents Of The University Of Minnesota	Prrs viruses, infectious clones, mutants thereof, and methods of use
EP1968630B1 (en)	2005-12-29	2018-01-24	Boehringer Ingelheim Vetmedica, Inc.	Multivalent pcv2 immunogenic compositions
CN100523177C (zh) *	2007-01-09	2009-08-05	中国农业科学院哈尔滨兽医研究所	猪繁殖与呼吸综合症病毒弱毒疫苗株及其应用
KR101653177B1 (ko) *	2008-08-25	2016-09-01	베링거잉겔하임베트메디카인코퍼레이티드	고병원성 돼지 생식기 및 호흡기 증후군(ｈｐｐｒｒｓ)에 대한 백신
AR078253A1 (es) *	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
ES2550258T3 (es)	2011-02-17	2015-11-05	Boehringer Ingelheim Vetmedica Gmbh	Nueva cepa del PRRSV europea
SG192821A1 (en)	2011-02-17	2013-09-30	Boehringer Ingelheim Vetmed	Commercial scale process for production of prrsv
KR101281361B1 (ko) *	2011-07-18	2013-07-02	서울대학교산학협력단	북미형 돼지 생식기 호흡기 증후군 바이러스 예방 백신 조성물 및 이를 포함하는 혼합백신 조성물
EP2737059A1 (en)	2011-07-29	2014-06-04	Boehringer Ingelheim Vetmedica GmbH	Novel prrs virus inducing type i interferon in susceptible cells
US9187731B2 (en)	2011-07-29	2015-11-17	Boehringer Ingelheim Vetmedica Gmbh	PRRS virus inducing type I interferon in susceptible cells
CA2872789C (en) *	2012-05-17	2019-09-03	Zoetis Llc	Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
WO2014089117A1 (en)	2012-12-07	2014-06-12	The Board Of Trustees Of The University Of Illinois	Porcine reproductive and respiratory syndrome virus compositions and uses thereof
WO2014150822A2 (en)	2013-03-15	2014-09-25	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
EA039060B1 (ru)	2013-12-20	2021-11-29	Бёрингер Ингельхайм Ветмедика Гмбх	Вариант вируса ppcc, способ его получения с помощью молекулы нуклеиновой кислоты, конструкции днк или клетки и его применение для лечения и профилактики ррсс
PT3534939T (pt)	2016-11-03	2023-04-20	Boehringer Ingelheim Vetmedica Gmbh	Vacina contra parvovírus porcino e vírus da síndrome reprodutiva e respiratória porcina e métodos da sua produção

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69201441T3 (de) *	1991-06-06	2008-12-04	Boehringer Ingelheim Vetmedica Gmbh	Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
CA2076744C (en) *	1991-08-26	2000-06-27	Danny W. Chladek	Viral agent associated with mystery swine disease
DE601062T1 (de) *	1991-08-26	1995-05-18	David Allen Benfield	Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas).
AU2684792A (en) *	1991-10-14	1993-05-21	Akzo Nobel N.V.	Porcine reproductive respiratory syndrome vaccine and diagnostic
KR100374295B1 (ko) *	1993-02-08	2003-12-24	바이엘 코포레이션	돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도
ES2165405T3 (es) *	1994-04-11	2002-03-16	Akzo Nobel Nv	Cepas de vacuna europeas del virus del sindrome reproductor y respiratorio porcino (prrsv).

1996
- 1996-01-25 ES ES09600168A patent/ES2102971B1/es not_active Expired - Fee Related
- 1996-04-12 UA UA97105158A patent/UA68326C2/uk unknown
- 1996-12-04 KR KR1019970706672A patent/KR19980703268A/ko not_active Abandoned
- 1996-12-04 US US08/930,330 patent/US6001370A/en not_active Expired - Fee Related
- 1996-12-04 WO PCT/ES1996/000234 patent/WO1997027288A1/es not_active Ceased
- 1996-12-04 CN CN96194133A patent/CN1185806A/zh active Pending
- 1996-12-04 PL PL96322455A patent/PL185841B1/pl not_active IP Right Cessation
- 1996-12-04 JP JP9526571A patent/JP3068204B2/ja not_active Expired - Lifetime
- 1996-12-04 CZ CZ19973377A patent/CZ286766B6/cs not_active IP Right Cessation
- 1996-12-04 HU HU9801124A patent/HUP9801124A3/hu unknown
- 1996-12-04 BR BR9604888A patent/BR9604888A/pt not_active Application Discontinuation
- 1996-12-04 EP EP96940665A patent/EP0835929A1/en not_active Withdrawn
- 1996-12-04 CA CA002216436A patent/CA2216436A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL322455A1 (en)	1998-02-02
HUP9801124A3 (en)	1999-09-28
WO1997027288A1 (es)	1997-07-31
BR9604888A (pt)	1998-12-15
ES2102971A1 (es)	1997-08-01
KR19980703268A (ko)	1998-10-15
MX9707302A (es)	1998-06-30
CZ286766B6 (en)	2000-06-14
JPH10507372A (ja)	1998-07-21
ES2102971B1 (es)	1998-03-01
PL185841B1 (pl)	2003-08-29
CN1185806A (zh)	1998-06-24
US6001370A (en)	1999-12-14
CA2216436A1 (en)	1997-07-31
EP0835929A1 (en)	1998-04-15
HUP9801124A2 (hu)	1998-08-28
CZ337797A3 (cs)	1998-03-18
JP3068204B2 (ja)	2000-07-24

Publication	Publication Date	Title
UA68326C2 (en)	2004-08-16	An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs
US5510258A (en)	1996-04-23	Porcine reproductive and respiratory syndrome virus antigen and processes for the preparation and use of said antigen in vaccines and diagnostics
Seo et al.	1997	Specific cytotoxic T lymphocytes are involved in in vivo clearance of infectious bronchitis virus
Afshar et al.	1990	Viruses associated with bovine semen.
Wensvoort et al.	1988	Bovine viral diarrhoea virus infections in piglets born to sows vaccinated against swine fever with contaminated vaccine
KR100484041B1 (ko)	2005-08-18	돼지생식 및 호흡증후군 바이러스의 유럽백신 균주
Scherer et al.	2001	Experimental infection of pregnant ewes with bovine viral diarrhea virus type-2 (BVDV-2): effects on the pregnancy and fetus
Balasuriya et al.	2018	Equine viral arteritis: a respiratory and reproductive disease of significant economic importance to the equine industry
Mengeling et al.	1979	Efficacy of an inactivated virus vaccine for prevention of porcine parvovirus-induced reproductive failure
Lupton et al.	1980	Evaluation of experimental subunit vaccines for infectious bovine rhinotracheitis
Beer et al.	1997	Cytotoxic T-lymphocyte responses in cattle infected with bovine viral diarrhea virus
Fulton et al.	1997	Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay
Salt	2019	Persistence of foot-and-mouth disease virus
Beer et al.	2000	A new inactivated BVDV genotype I and II vaccine: an immunisation and challenge study with BVDV genotype I
Paton et al.	1999	Foetal cross-protection experiments between type 1 and type 2 bovine viral diarrhoea virus in pregnant ewes
CZ273798A3 (cs)	1999-02-17	Vakcína a způsob ochrany proti reprodukčnímu a respiračnímu syndromu vepřů
Carlsson et al.	1991	Protective effect of an ISCOM bovine virus diarrhoea virus (BVDV) vaccine against an experimental BVDV infection in vaccinated and non-vaccinated pregnant ewes
Bruschke et al.	1999	An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep
JPH08188515A (ja)	1996-07-23	組織培養物において効能のあるトキソプラズマゴンデイブラデイゾイトワクチンの生産
De Smit et al.	2000	Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics
Toth	1982	Trypsin-enhanced replication of neonatal calf diarrhea coronavirus in bovine embryonic lung cells
Collen et al.	2000	Single amino acid differences are sufficient for CD4+ T-cell recognition of a heterologous virus by cattle persistently infected with bovine viral diarrhea virus
Kortekaas et al.	2010	Rational design of a classical swine fever C-strain vaccine virus that enables the differentiation between infected and vaccinated animals
CA2224309C (en)	2011-01-25	Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
Edwards et al.	1995	Comparative studies of border disease andclosely related virus infections in experimental pigs and sheep